Sydney, 1 February: Noxopharm announces that it has entered into a research agreement with the University of Hong Kong to conduct research into the use of the drug idronoxil (NOX66 active ingredient) to treat brain cancer.
In parallel to the NOX66 clinical program currently being rolled out, the Company has an extensive R&D program in place. This program involves a number of previously undisclosed oncology and non-oncology pre-clinical activities, all intended to add to the Company’s drug development pipeline. The Company previously has said that it will provide details of those R&D activities as confidentiality issues and patent lodgements allow. This is the first of those notifications.
For further information please download PDF attached:
Download this document
